Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

Effects of ghrelin, growth hormone-releasing peptide-6

Randomized Controlled Trial . 2010 Oct;59(10):1536-42. doi: 10.1016/j.metabol.2010.01.021. Epub 2010 Mar 1. Affiliations PMID: 20189610 DOI: 10.1016/j.metabol.2010.01.021 Free article Randomized Controlled Trial Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus Larissa Bianca Paiva Cunha de Sá et al. Metabolism. 2010 Oct. Free article Abstract In type 1 diabetes mellitus (T1DM), growth hormone (GH) responses to provocative stimuli are normal or exaggerated, whereas the hypothalamic-pituitary-adrenal axis has been less studied. Ghrelin is a GH secretagogue that also increases adrenocorticotropic hormone (ACTH) and cortisol levels, similarly to GH-releasing peptide-6 (GHRP-6). Ghrelin's effects in patients with T1DM have not been evaluated. We therefore studied GH, ACTH, and cortisol responses to ghrelin and GHRP-6 in 9 patients with T1DM and 9 contr

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

Randomized Controlled Trial

. 2010 Oct;59(10):1536-42.

doi: 10.1016/j.metabol.2010.01.021. Epub 2010 Mar 1.

Affiliations

PMID: 20189610 DOI: 10.1016/j.metabol.2010.01.021

Free article

Randomized Controlled Trial

Effects of ghrelin, growth hormone-releasing peptide-6, and growth hormone-releasing hormone on growth hormone, adrenocorticotropic hormone, and cortisol release in type 1 diabetes mellitus

Larissa Bianca Paiva Cunha de Sá et al. Metabolism. 2010 Oct.

Free article

Abstract

In type 1 diabetes mellitus (T1DM), growth hormone (GH) responses to provocative stimuli are normal or exaggerated, whereas the hypothalamic-pituitary-adrenal axis has been less studied. Ghrelin is a GH secretagogue that also increases adrenocorticotropic hormone (ACTH) and cortisol levels, similarly to GH-releasing peptide-6 (GHRP-6). Ghrelin's effects in patients with T1DM have not been evaluated. We therefore studied GH, ACTH, and cortisol responses to ghrelin and GHRP-6 in 9 patients with T1DM and 9 control subjects. The GH-releasing hormone (GHRH)-induced GH release was also evaluated. Mean fasting GH levels (micrograms per liter) were higher in T1DM (3.5 ± 1.2) than in controls (0.6 ± 0.3). In both groups, ghrelin-induced GH release was higher than that after GHRP-6 and GHRH. When analyzing Δ area under the curve (ΔAUC) GH values after ghrelin, GHRP-6, and GHRH, no significant differences were observed in T1DM compared with controls. There was a trend (P = .055) to higher mean basal cortisol values (micrograms per deciliter) in T1DM (11.7 ± 1.5) compared with controls (8.2 ± 0.8). No significant differences were seen in ΔAUC cortisol values in both groups after ghrelin and GHRP-6. Mean fasting ACTH values were similar in T1DM and controls. No differences were seen in ΔAUC ACTH levels in both groups after ghrelin and GHRP-6. In summary, patients with T1DM have normal GH responsiveness to ghrelin, GHRP-6, and GHRH. The ACTH and cortisol release after ghrelin and GHRP-6 is also similar to controls. Our results suggest that chronic hyperglycemia of T1DM does not interfere with GH-, ACTH-, and cortisol-releasing mechanisms stimulated by these peptides.

Copyright © 2010 Elsevier Inc. All rights reserved.

PubMed Disclaimer

Connected topics

Follow this recovery question